The Genetics and Neurodegenerative Diseases group aims to identify the main genetic pathways involved in Parkinson’s disease and other neurodegenerative disorders. To do so, we will use single-cell RNA sequencing, which will allow us to characterize the main genetic alterations with cell-type specificity, using postmortem brain tissue from patients, cells from peripheral fluid samples donated by patients, and tissue from animal models. The data will be validated using histological techniques such as immunofluorescence and in situ hybridization, as well as spatial transcriptomics techniques such as in situ sequencing. The high sensitivity of the techniques used will enable us to identify the cell types most affected and the genes most heavily implicated, which will guide the exploration of new therapeutic targets and treatment approaches.